References For Dosing ZOMETA® For Tumour-Induced Hypercalcaemia (TIH)

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA dosing and administration for TIH

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

References: 1. ZOMETA^® Summary of Product Characteristics. Novartis Pharma AG. 2. Major P. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.Oncologist. 2002;7:481-491. 3. ZOMETA US Prescribing Information. Novartis Pharmaceuticals Corporation.

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.